One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer
The arrival of antibody drug conjugates in nasopharyngeal cancer
Three-month dual antiplatelet therapy after percutaneous coronary intervention: time for a new standard
First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia
Simultaneous outbreaks of Ebola, cholera, mpox, and measles in DR Congo in 2025
Community-controlled research for disruption-resilient partnerships
CheckMate 8HW and the future of dual immunotherapy – Authors' reply
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
